JTV 519

Drug Profile

JTV 519

Alternative Names: JTV-519; K201 - Merck; K201 - Sequel

Latest Information Update: 19 Aug 2015

Price : $50

At a glance

  • Originator Aetas Pharma; Japan Tobacco
  • Developer Sequel Pharmaceuticals
  • Class Small molecules; Thiazepines
  • Mechanism of Action Calcium channel antagonists; Potassium channel antagonists; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atrial fibrillation; Cancer; Heart failure; Myocardial infarction

Most Recent Events

  • 13 May 2011 Sequel Pharmaceuticals terminates phase II trial in Atrial fibrillation in Denmark and Israel (NCT01259622)
  • 13 May 2011 Sequel Pharmaceuticals terminates phase II trial in Atrial fibrillation in US and EU (NCT01067833)
  • 12 Sep 2007 NovaCardia has been acquired by Merck and Co
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top